We offer a comprehensive range of products and services to support customers throughout the entire RNA medicine development process, from initial design to commercial manufacturing.
As the market demand for RNA therapeutics such as siRNA and sgRNA is anticipated to grow substantially over the next decade, there is a need for scalable, cost-effective, and sustainable manufacturing solutions.
Chemoenzymatic ligation is a promising approach for siRNA and sgRNA manufacturing, offering enhanced purity, increased yield, and reduced environmental impact. This innovative technology provides an optimal solution to meet the anticipated surge in demand for these drugs over the coming decade.
At TIDES USA 2025, our CTO, David Butler presented the latest advancements in Hongene's chemoenzymatic ligation platform for oligonucleotides synthesis and provided strategic insights that will help researchers and companies navigate drug development process using the ligation technology.
David Butler
Chief Technology Officer
David Butler is the Chief Technology Officer at Hongene Biotech Corporation, a fully integrated raw materials supplier and CDMO services provider that is focused on the RNA manufacturing space, the scope of which includes mRNA therapeutics, vaccines, siRNA, antisense oligonucleotides, diagnostics, and gene editing.
Prior to Hongene, he led organizations driving drug discovery and development of oligonucleotide therapeutics as VP and Head of Medicinal Chemistry at Wave Life Sciences, VP and Head of Therapeutics Development at Alltrna, and VP and Head of Chemistry at Korro Bio.
He also spent time as a Principal Scientist at Alnylam Pharmaceuticals, developing early LNP technologies for siRNA delivery that were the progenitors of those used for mRNA-related products today. He is passionate about team building, working with individuals and companies to help them succeed, and leveraging novel technologies to advance RNA medicines more efficiently and safely.
